Journal
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume 17, Issue 5, Pages 617-625Publisher
WILEY
DOI: 10.1111/jcmm.12036
Keywords
adipose tissue stem cells; mesenchymal stem cells; myocardial infarction; cell therapy; connexin-43
Categories
Funding
- NIH [1R03TW008709]
- FAPEMIG
- CNPq
Ask authors/readers for more resources
Cardiovascular diseases are the number one cause of death globally and are projected to remain the single leading cause of death. Treatment options abounds, although efficacy is limited. Recent studies attribute discrete and ephemeral benefits to adult stem cell therapies, indicating the urge to improve stem cell based-therapy. In this study, we show that priming mesenchymal stem cells (MSC) towards cardiomyogenic lineage enhances their beneficial effects in vivo as treatment option for acute phase myocardial infarction. MSC were primed using cardiomyogenic media for 4days, after which peak expression of key cardiomyogenic genes are reached and protein expression of Cx-43 and sarcomeric -actinin are observed. MSC and primed MSC (pMSC) were characterized in vitro and used to treat infarcted rats immediately after left anterior descending (LAD) occlusion. Echocardiography analysis indicated that MSC-treated myocardium presented discrete improvement in function, but it also showed that pMSC treatment lead to superior beneficial results, compared with undifferentiated MSC. Seven days after cell injection, MSC and pMSC could still be detected in the myocardium. Connexin-43 expression was quantified through immunoblotting, and was superior in pMSC, indicating that this could be a possible explanation for the superior performance of pMSC therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available